National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Multiple Myeloma and Other Plasma Cell Neoplasms Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 09/08/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Amyloidosis






Multiple Myeloma






Isolated Plasmacytoma of Bone






Extramedullary Plasmacytoma






Waldenström Macroglobulinemia (Lymphoplasmacytic Lymphoma)






Monoclonal Gammopathy of Undetermined Significance






Refractory Plasma Cell Neoplasm






Get More Information From NCI






Changes to This Summary (09/08/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
General Information

Note: Estimated new cases and deaths from multiple myeloma in the United States in 2008:[1]

  • New cases: 19,920.
  • Deaths: 10,690.

Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 to 30 months and a 10-year survival of 3%. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. The disease is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal (or myeloma) protein (M protein) in the serum and/or urine, along with various clinical parameters, such as the hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure. The stage of the disease at presentation is a strong determinant of survival, but it has little influence on the choice of therapy since almost all patients, except for rare patients with solitary bone tumors or extramedullary plasmacytomas, have generalized disease. Treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease.[2]

The initial approach to the patient is to establish the diagnosis by:

  1. Detection of an M protein in the serum or urine.
  2. Detection of greater than 10% of plasma cells on a bone marrow examination.
  3. Detection of lytic bone lesions or generalized osteoporosis in skeletal x-rays.
  4. Presence of soft tissue plasmacytomas.

References

  1. American Cancer Society.: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008. Also available online. Last accessed October 1, 2008. 

  2. Rajkumar SV, Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80 (10): 1371-82, 2005.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov